Background: People with multiple sclerosis have reduced walking speed and impaired gait pattern. Prolonged release-fampridine is a potassium channel blocker that improves nerve conduction in patients with multiple sclerosis, leading to walking benefits. Whether fampridine alters gait pattern is unknown. Methods: In this crossover, randomized controlled trial, patients with multiple sclerosis were tested for responder status during a 4-week run-in period. Patients were considered responders if they improved their 25-ft walk test by 10% and improved their perceived walking capacity. Responders were randomized to prolonged release- fampridine (10 mg b.i.d.) or placebo for a 6-week period. After a 2-week wash-out period, they were allo- cated t...
Prolonged-release (PR) fampridine is the only approved medication to improve walking in multiple scl...
Prolonged-release (PR) fampridine is the only approved medication to improve walking in multiple scl...
Prolonged-release (PR) fampridine is approved to treat walking impairment in persons with multiple s...
BACKGROUND Prolonged-release fampridine (PR-fampridine, 4-aminopyridine) increases walking speed in...
Objective: The aim of this study was to explore the modification of gait parameters, in relation wit...
International audienceBACKGROUND: Gait impairment is one of the most disabling symptoms in people wi...
BackgroundWalking impairment is a hallmark of multiple sclerosis (MS). It affects>90% of individu...
BackgroundWalking impairment is a hallmark of multiple sclerosis (MS). It affects>90% of individuals...
Objective: To expand upon the limited knowledge of the long-term effects of prolonged-release (PR) f...
Publisher Copyright: © 2021 Laeknafelag Islands. All rights reserved.INTRODUCTION: Fampridine is a d...
Background: Gait impairment is common in multiple sclerosis (MS) and negatively impacts patients’ he...
Objectives: To summarize the evidence on the benefits of prolonged-release(PR)-fampridine among pati...
Gait dysfunction is common in patients with multiple sclerosis (PwMS). Treatment with prolonged-rele...
AbstractProlonged-release (PR) fampridine is approved to treat walking impairment in persons with mu...
Background: Impaired walking capacity is a frequent confinement in Multiple Sclerosis (MS). Patients...
Prolonged-release (PR) fampridine is the only approved medication to improve walking in multiple scl...
Prolonged-release (PR) fampridine is the only approved medication to improve walking in multiple scl...
Prolonged-release (PR) fampridine is approved to treat walking impairment in persons with multiple s...
BACKGROUND Prolonged-release fampridine (PR-fampridine, 4-aminopyridine) increases walking speed in...
Objective: The aim of this study was to explore the modification of gait parameters, in relation wit...
International audienceBACKGROUND: Gait impairment is one of the most disabling symptoms in people wi...
BackgroundWalking impairment is a hallmark of multiple sclerosis (MS). It affects>90% of individu...
BackgroundWalking impairment is a hallmark of multiple sclerosis (MS). It affects>90% of individuals...
Objective: To expand upon the limited knowledge of the long-term effects of prolonged-release (PR) f...
Publisher Copyright: © 2021 Laeknafelag Islands. All rights reserved.INTRODUCTION: Fampridine is a d...
Background: Gait impairment is common in multiple sclerosis (MS) and negatively impacts patients’ he...
Objectives: To summarize the evidence on the benefits of prolonged-release(PR)-fampridine among pati...
Gait dysfunction is common in patients with multiple sclerosis (PwMS). Treatment with prolonged-rele...
AbstractProlonged-release (PR) fampridine is approved to treat walking impairment in persons with mu...
Background: Impaired walking capacity is a frequent confinement in Multiple Sclerosis (MS). Patients...
Prolonged-release (PR) fampridine is the only approved medication to improve walking in multiple scl...
Prolonged-release (PR) fampridine is the only approved medication to improve walking in multiple scl...
Prolonged-release (PR) fampridine is approved to treat walking impairment in persons with multiple s...